Orgenesis (OTCMKTS:ORGS) Upgraded to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Orgenesis (OTCMKTS:ORGS) from a sell rating to a hold rating in a report published on Tuesday morning, Zacks.com reports.

According to Zacks, “Orgenesis, Inc. is a biopharmaceutical company. It focused on developing its trans-differentiation technologies for diabetes. The company deals with the combination of cell-based therapy and regenerative medicine into clinical development. Its operating segment consists of Contract Development and Manufacturing Organization and Cellular Therapy Business. Contract Development and Manufacturing Organization segment activity includes MaSTherCell, which specializes in cell therapy development for advanced medicinal products. Cellular Therapy Business segment activity is based on its technology which demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell like insulin producing cells for patients with Type 1 Diabetes. Orgenesis, Inc. is headquartered in Germantown, MD. “

Shares of ORGS stock opened at $4.09 on Tuesday. Orgenesis has a one year low of $3.78 and a one year high of $9.50.



Several hedge funds have recently modified their holdings of ORGS. BlackRock Inc. lifted its holdings in Orgenesis by 44.6% in the fourth quarter. BlackRock Inc. now owns 28,886 shares of the company’s stock worth $135,000 after acquiring an additional 8,909 shares during the last quarter. Northern Trust Corp bought a new position in Orgenesis in the fourth quarter worth about $70,000. Geode Capital Management LLC bought a new position in Orgenesis in the fourth quarter worth about $212,000. Vanguard Group Inc. lifted its holdings in Orgenesis by 63.2% in the third quarter. Vanguard Group Inc. now owns 236,324 shares of the company’s stock worth $1,309,000 after acquiring an additional 91,507 shares during the last quarter. Finally, Vanguard Group Inc lifted its holdings in Orgenesis by 63.2% in the third quarter. Vanguard Group Inc now owns 236,324 shares of the company’s stock worth $1,309,000 after acquiring an additional 91,507 shares during the last quarter.

Orgenesis Company Profile

Orgenesis Inc is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company’s subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products.

Read More: What is Compound Interest?

Get a free copy of the Zacks research report on Orgenesis (ORGS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.